Tijek postupka procjene izvedbenog stanja izmjere – problemi i izazovi

The purpose of this paper is to present the range of surveying works carried out during geodetic as-built inventory of buildings and utility infrastructure. The theoretical part of this essay complies grounds for legal basis on territory of Poland, which are core part of geodetic and cartographic studies. Moreover, the phases of geodetic as-built inventory are being discussed, in the light of applicable rules. Particular attention is being paid to the topic of situational and height measurements. The paper discusses methods of measurement used, precision groups and objects subjected to inventory measurement are being listed. The practical part of this paper regards surveying as-built inventory of single-family house. In this study we discuss the consequential procedures that contractors need to fallow during the construction process, this includes preliminary actions, field work, and individual elaboration of the findings. Post-completion documentation, gathered in the form of technical frame, after obtaining a positive verification test result was included in the Head Office of Geodesy and Cartography.Ovaj članak ima za svrhu prikazati opseg geodetskih radova provedenih na popisu izvedbenih stanja zgrada i komunalne infrastrukture. Teorijski dio ovog rada donosi pravila za pravnu osnovu na teritoriju Poljske, koja su ključni dio geodetskih i kartografskih studija. Povrh toga, razmatraju se faze popisa izvedbenog stanja geodetskih radova s obzirom na važeća pravila. Posebna je pažnja posvećena temi situacijskih i visinskih mjerenja. U radu se razmatraju primijenjene metode mjerenja te su popisane skupine preciznosti i skupine objekata koje su predmet inventarnih mjerenja. Praktični dio ovog rada uzima u obzir izmjeru izvedenog inventara jedne obiteljske kuće. U ovoj studiji razmatramo posljedične postupke koje građevinari moraju slijediti tijekom procesa gradnje, a to uključuje preliminarne radnje, terenski rad i pojedinačnu elaboraciju rezultata. Naknadna dokumentacija prikupljena u obliku tehničkog okvira, nakon dobivanja pozitivnog rezultata testa verifikacije, dostavljena je Glavnom uredu za geodeziju i kartografiju

Tijek postupka procjene izvedbenog stanja izmjere – problemi i izazovi

The purpose of this paper is to present the range of surveying works carried out during geodetic as-built inventory of buildings and utility infrastructure. The theoretical part of this essay complies grounds for legal basis on territory of Poland, which are core part of geodetic and cartographic studies. Moreover, the phases of geodetic as-built inventory are being discussed, in the light of applicable rules. Particular attention is being paid to the topic of situational and height measurements. The paper discusses methods of measurement used, precision groups and objects subjected to inventory measurement are being listed. The practical part of this paper regards surveying as-built inventory of single-family house. In this study we discuss the consequential procedures that contractors need to fallow during the construction process, this includes preliminary actions, field work, and individual elaboration of the findings. Post-completion documentation, gathered in the form of technical frame, after obtaining a positive verification test result was included in the Head Office of Geodesy and Cartography.Ovaj članak ima za svrhu prikazati opseg geodetskih radova provedenih na popisu izvedbenih stanja zgrada i komunalne infrastrukture. Teorijski dio ovog rada donosi pravila za pravnu osnovu na teritoriju Poljske, koja su ključni dio geodetskih i kartografskih studija. Povrh toga, razmatraju se faze popisa izvedbenog stanja geodetskih radova s obzirom na važeća pravila. Posebna je pažnja posvećena temi situacijskih i visinskih mjerenja. U radu se razmatraju primijenjene metode mjerenja te su popisane skupine preciznosti i skupine objekata koje su predmet inventarnih mjerenja. Praktični dio ovog rada uzima u obzir izmjeru izvedenog inventara jedne obiteljske kuće. U ovoj studiji razmatramo posljedične postupke koje građevinari moraju slijediti tijekom procesa gradnje, a to uključuje preliminarne radnje, terenski rad i pojedinačnu elaboraciju rezultata. Naknadna dokumentacija prikupljena u obliku tehničkog okvira, nakon dobivanja pozitivnog rezultata testa verifikacije, dostavljena je Glavnom uredu za geodeziju i kartografiju

Віддалений прогноз хворих з серцевою недостатністю та поліморфізм Gln27Glu гену β2-адренорецепторів

The aim: to determine the influence of Gln27Glu polymorphism of the β2-adrenergic receptor gene on the long-term prognosis of patients with heart failure.Material and methods. The study included 200 patients with heart failure. The clinical course of the disease was evaluated and a genetic study of Gln27Glu polymorphism of the β2-adrenergic receptor gene was done. The material for molecular-genetic research was peripheral blood leukocytes of patients. Isolation of genomic DNA from blood leukocytes for molecular genetic studies was carried out using a commercial "DNA-sorb-B" kit in accordance with the instruction for the kit. Primer sequences were used for the polymerase chain reaction.Results. An analysis of the distribution of genotypes of the polymorphic Gln27Glu locus of the β2-adrenoreceptor gene in patients with heart failure showed that the genotype Gln27Gln occurs in 33 % of cases; Glu27Glu – in 13 %; Gln27Glu – in 54 %. Carriers of the mutant allele (G) of the β2-adrenoreceptor gene have a high incidence of atrial fibrillation (35.6 % vs. 7.7 %) over 3 years of follow-up. Hospitalization (42.0 % versus 19.2 %) and the frequency of reaching the combined end point (hospitalization + death) (54.0 % vs. 30.8 %) are greater among patients who carry the mutated G allele compared to homozygous patients with the "wild" allele C, for 3 years of observation. Polymorphism of the Gln27Glu gene of the β2-adrenoreceptor does not significantly affect the three-year mortality of patients with heart failure.Conclusions. The carriers of the mutant allele (G) of β2-adrenergic receptors have a high incidence of atrial fibrillation, hospitalization and the achievement of a combined end point (hospitalization + death) for 3 years of observation, compared to homozygous patients with the "wild-type" allele C. The polymorphism of the gene Gln27Glu of the β2-adrenoceptors does not affect the three-year mortality of patients with heart failureЦель работы: определить влияние полиморфизма Gln27Glu гена β2-адренорецепторов на отдаленный прогноз больных с сердечной недостаточностью.Материал и методы. В исследование включено 200 больных с сердечной недостаточностью. Оценивали клиническое течение заболевания и проводили генетическое исследование полиморфизма Gln27Glu гена β2-адренорецепторов. Материалом для молекулярно-генетического исследования служили лейкоциты периферической крови пациентов. Выделение геномной ДНК из лейкоцитов крови для молекулярно-генетических исследований осуществляли с помощью коммерческого набора «ДНК-сорб-В» в соответствии с инструкцией к набору. Для полимеразной цепной реакции использовали праймерные последовательности.Результаты. Анализ распределения генотипов полиморфного локуса Gln27Glu гена β2-адренорецепторов у больных с сердечной недостаточностью показал, что генотип Gln27Gln встречается в 33 % случаев; Glu27Glu - в 13 %; Gln27Glu - в 54 %. Носители мутантной аллели (G) гена β2-адренорецепторов имеют большую частоту развития фибрилляции предсердий (35,6 % против 7,7 %) на протяжении 3 лет наблюдения. Госпитализация (42,0 % против 19,2 %) и частота достижения комбинированной конечной точки (госпитализация + смерть) (54,0 % против 30,8 %) больше среди больных, которые являются носителями мутированной аллели G, по сравнению с гомозиготными пациентами по "дикой" аллели C, на протяжении 3 лет наблюдения. Полиморфизм гена Gln27Glu гена β2-адренорецепторов достоверно не влияет на трехлетнюю смертность больных с сердечной недостаточностью.Выводы. Носители мутантной аллели (G) β2-адренорецепторов имеют большую частоту развития фибрилляции предсердий, госпитализации и достижения комбинированной конечной точки (госпитализация + смерть) на протяжении 3 лет наблюдения, в сравнении с гомозиготными пациентами по "дикой" аллели С. Полиморфизм гена Gln27Glu гена β2-адренорецепторов не влияет на трехлетнюю смертность больных с сердечной недостаточностьюМета роботи: визначити вплив поліморфізму Gln27Glu гену β2-адренорецепторів на віддалений прогноз хворих з серцевою недостатністю.Матеріал та методи. До дослідження включено 200 хворих з серцевою недостатністю. Оцінювали клінічний перебіг захворювання та проводили генетичне дослідження поліморфізму Gln27Glu гену β2-адренорецепторів. Матеріалом для молекулярно-генетичного дослідження були лейкоцити периферичної крові пацієнтів. Виділення геномної ДНК із лейкоцитів крові для молекулярно-генетичних досліджень здійснювали за допомогою комерційного набору «ДНК-сорб-В» у відповідності з інструкцією до набору. Для полімеразно-ланцюгової реакції використовували праймерні послідовності.Результати. Аналіз розподілу генотипів поліморфного локусу Gln27Glu гена β2-адренорецепторів у хворих з серцевою недостатністю показав, що генотип Gln27Gln зустрічається у 33 % випадків; Glu27Glu – у 13 %; Gln27Glu – у 54 %. Носії мутованого алелю (G) b2-адренорецепторів мали більшу частоту розвитку фібриляції передсердь (35,6 % проти 7,7 %) протягом 3 років спостереження. Госпіталізація (42,0 %, проти 19,2 %) та частота досягнення комбінованої кінцевої точки (госпіталізація + смерть) (54,0 % проти 30,8 %) більша серед хворих, що є носіями мутованого алелю G, порівнюючи з гомозиготними пацієнтами за „диким” алелем С, протягом 3 років спостереження. Поліморфізм гену Gln27Glu гена β2-адренорецепторів вірогідно не впливає на трьохрічну смертність хворих з серцевою недостатністю. Висновки. Носії мутованого алелю (G) b2-адренорецепторів мають більшу частоту розвитку фібриляції передсердь, госпіталізації з приводу декомпенсації серцевої недостатністю та досягнення комбінованої кінцевої точки (госпіталізація + смерть) протягом 3 років спостереження, порівнюючи з гомозиготними пацієнтами за „диким” алелем С, протягом 3 років спостереженн

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

BACKGROUND Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-tovery-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β2-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β2-agonist salmeterol in preventing exacerbations of COPD. METHODS In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year. RESULTS A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P<0.001). Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001), reduced the annual number of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P=0.002), and reduced the annual number of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P<0.001). Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups. There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group. CONCLUSIONS These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

BACKGROUND Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

USAGE OF THE GLOBAL NAVIGATION SATELLITE SYSTEMS IN SAFETY AND PROTECTION ISSUES

Currently, global navigation satellite systems (GNSS) play a key role in the broad field of security and human life. In principle, almost every area of human activity (for example, mining, energy or construction) systems related to saving human life are introduced. Generally, satellite navigation is an indispensable element of this type of systems. In this paper, authors present basic principles of the GNSS operation and the current state of knowledge about usage of the global navigation satellite systems in the area of safety, protection and rescue issues

Geoinformational system of rescue services

Geoportal is an indispensable tool for processing data related to city infrastructure, life support systems; for the analysis of statistics of fires and other emergency situations in the city; to create thematic layers of electron-vector maps showing the city’s infrastructure and other information necessary for the management of the SNS units; for identification of fire risks for residential buildings and public buildings of Lviv city and mapping them according to the risk levels in the form of a risk map. The analysis of the city’s infrastructure allows us to study in detail the problematic issues related to fire and technological safety. The geoportal and its cartographic information of the information will allow the head of the rescue unit, during the post-emergency situation, to find the information necessary for the effective performance of rescue operations and to assess the potential risks

C60 fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes

Abstract Background C60 fullerene-based nanoformulations are proposed to have a direct toxic effect on tumor cells. Previous investigations demonstrated that C60 fullerene used alone or being conjugated with chemotherapeutic agents possesses a potent anticancer activity. The main aim of this study was to investigate the effect of C60 fullerene and its nanocomplexes with anticancer drugs on human phagocyte metabolic profile in vitro. Methods Analysis of the metabolic profile of phagocytes exposed to C60 fullerene in vitro revealed augmented phagocytic activity and down-regulated reactive nitrogen species generation in these cells. Additionally, cytofluorimetric analysis showed that C60 fullerene can exert direct cytotoxic effect on normal and transformed phagocytes through the vigorous induction of intracellular reactive oxygen species generation. Results Cytotoxic action as well as the pro-oxidant effect of C60 fullerene was more pronounced toward malignant phagocytes. At the same time, C60 fullerenes have the ability to down-regulate the pro-oxidant effect of cisplatin on normal cells. These results indicate that C60 fullerenes may influence phagocyte metabolism and have both pro-oxidant and antioxidant properties. Conclusions The antineoplastic effect of C60 fullerene has been observed by direct toxic effect on tumor cells, as well as through the modulation of the functions of effector cells of antitumor immunity

Effects of the lercanidipine - Enalapril combination vs. The corresponding monotherapies on home blood pressure in hypertension: Evidence from a large database

103siObjective: To compare a combination of a dihydropyridine calcium-channel blocker with an angiotensin converting enzyme inhibitor vs. monotherapy with one or the other drug and placebo for their effects on home blood pressure (HBP). Methods: After a 2-week placebo wash-out, patients with an elevated office blood pressure (BP) (diastolic 100–109 and systolic <180 mmHg) and HBP (diastolic 85 mmHg) were randomized double-blind to a 10-week treatment with placebo, lercanidipine, 10 or 20mg daily, enalapril, 10 or 20mg daily, or the four possible combinations. In addition to office BP, HBP was self-measured via a validated semiautomatic device twice in the morning and twice in the evening during the 7 days before randomization and at the end of treatment. Baseline and treatment HBP values were separately averaged for each day, morning, evening or the whole monitoring period, excluding the first day. Day-by-day HBP variability was defined as the SD or the variation coefficient of the daily BP averages. Results: Eight hundred and fifty-four patients with valid HBP recordings at baseline and at the end of treatment were analyzed (intention-to-treat population). From the baseline value (147.011.6 mmHg) systolic/diastolic HBP showed a small reduction (average baseline-adjusted change: –1.8/–1.6 mmHg) with placebo, a more marked significant fall with monotherapies (8.8/5.9 mmHg, P<0.001/<0.001 vs. placebo) and even more with combination treatment (11.6/7.6 mmHg, P<0.001/ <0.001 vs. placebo and P<0.01/<0.05 vs. monotherapy). A similar pattern was observed for each of the days of the BP self-monitoring period as well as for either morning or evening values, although the difference between mono and combination treatment appeared to be consistently significant for the morning values only. Dayby- day systolic BP-SD was unaffected by placebo and slightly reduced by drug treatments, with no, however, significant changes in SBP-variation coefficient. Baseline and end of treatment HBP values showed a limited correlation with office BP values, this being particularly the case for treatment-induced changes (correlation coefficients: 0.37 for systolic and 0.45 for diastolic BP). Conclusion: This large HBP database shows that the lercanidipine–enalapril combination lowers HBP more effectively than the corresponding monotherapies and placebo, and that this greater effect is consistent between days.reservedmixedMancia, Giuseppe; Omboni, Stefano; Chazova, Irina; Coca, Antonio; Girerd, Xavier; Haller, Hermann; Parati, Gianfranco; Pauletto, Paolo; Pupek-Musialik, Danuta; Svyshchenko, Yevgeniya; Boye, Alain; Charrier, Bruno; Couffin, Yvon; Marmor, Philippe; Marty, Jacques; Navarre, Jean Louis; Ansari, Anwar; Büttner, Claudia; Kropp, Maximilian; Mehling, Heidrun; Paschen, Christine; Schenkenberger, Isabelle; Schneider, Helmut; Sperling, Karsten; Stübler, Petra; Von Behren, Volker; Lembo, Giuseppe; Scanferla, Flavio; Sechi, Leonardo Alberto; Gębala, Andrzej; Hoffmann, Andrzej; Janik, Krzysztof; Klimza-Masłowska, Anna; Kaczmarek, Barbara; Koźminski, Piotr; Makowiecka-Cies̈la, Magdalena; Mordaka, Robert; Nowakowski, Tomasz; Pasternak, Dariusz; Skibińska, Elzbieta; Sulik, Piotr; Szpajer, Michał; Walczewska, Jolanta; Zaczek, Marcin; Zienciuk-Krajka, Agnieszka; Alexeeva, Nadezhda; Bokarev, Igor; Chazova, Iina; Conrady, Alexandra; Emelyanov, Alexander; Galustyan, Anna; Idrisova, Elena; Khasanov, Niyaz; Khokhlov, Alexander; Libov, Igor; Reshetko, Olga; Sokurenko, German; Stryuk, Raisa; Tereshchenko, Sergey; Trofimov, Vasily; Zrazhevsky, Konstantin; Carlos Calvo, S.; De Teresa, Luis; Ferre, Raimon; García, Juan; Gil, Apolonia; Gil, Blas; Montenegro, Jesús; Oliván, Josefina; Ortiz, Jacinto; Pascual, José María; Rivera, Antonio; De Quevedo, José Antonio Sainz; Zúñiga, Manuel; Martinez, Valentin; Pujol, Montserrat; Bazylevych, Andriy; Gyrina, Olga; Ignatenko, Grygoriy; Kazymyrko, Vitaly; Khomazyuk, Tetyana; Kononenko, Lyudmyla; Korzh, Oleksii; Kovalenko, Volodymyr; Kuryata, Oleksander; Kushnir, Mykola; Lishnevska, Viktoriia; Lymar, Iurii; Ostrovska, Lidiia; Popik, Galyna; Rudyk, Yuriy; Shershnyova, Oxana; Sierkova, Valentyna; Storozhuk, Borys; Tseluyko, Vira; Vatutin, Mykola; Vayda, Myroslava; Vizir, Vadym; Volkov, Volodymyr; Voloshyna, Olena; Yagensky, Andriy; Zhurba, Svitlana; Zorin, ValeriiMancia, Giuseppe; Omboni, Stefano; Chazova, Irina; Coca, Antonio; Girerd, Xavier; Haller, Hermann; Parati, Gianfranco; Pauletto, Paolo; Pupek Musialik, Danuta; Svyshchenko, Yevgeniya; Boye, Alain; Charrier, Bruno; Couffin, Yvon; Marmor, Philippe; Marty, Jacques; Navarre, Jean Louis; Ansari, Anwar; Büttner, Claudia; Kropp, Maximilian; Mehling, Heidrun; Paschen, Christine; Schenkenberger, Isabelle; Schneider, Helmut; Sperling, Karsten; Stübler, Petra; Von Behren, Volker; Lembo, Giuseppe; Scanferla, Flavio; Sechi, Leonardo Alberto; Gębala, Andrzej; Hoffmann, Andrzej; Janik, Krzysztof; Klimza Masłowska, Anna; Kaczmarek, Barbara; Koźminski, Piotr; Makowiecka Cies̈la, Magdalena; Mordaka, Robert; Nowakowski, Tomasz; Pasternak, Dariusz; Skibińska, Elzbieta; Sulik, Piotr; Szpajer, Michał; Walczewska, Jolanta; Zaczek, Marcin; Zienciuk Krajka, Agnieszka; Alexeeva, Nadezhda; Bokarev, Igor; Chazova, Iina; Conrady, Alexandra; Emelyanov, Alexander; Galustyan, Anna; Idrisova, Elena; Khasanov, Niyaz; Khokhlov, Alexander; Libov, Igor; Reshetko, Olga; Sokurenko, German; Stryuk, Raisa; Tereshchenko, Sergey; Trofimov, Vasily; Zrazhevsky, Konstantin; Carlos Calvo, S.; De Teresa, Luis; Ferre, Raimon; García, Juan; Gil, Apolonia; Gil, Blas; Montenegro, Jesús; Oliván, Josefina; Ortiz, Jacinto; Pascual, José María; Rivera, Antonio; De Quevedo, José Antonio Sainz; Zúñiga, Manuel; Martinez, Valentin; Pujol, Montserrat; Bazylevych, Andriy; Gyrina, Olga; Ignatenko, Grygoriy; Kazymyrko, Vitaly; Khomazyuk, Tetyana; Kononenko, Lyudmyla; Korzh, Oleksii; Kovalenko, Volodymyr; Kuryata, Oleksander; Kushnir, Mykola; Lishnevska, Viktoriia; Lymar, Iurii; Ostrovska, Lidiia; Popik, Galyna; Rudyk, Yuriy; Shershnyova, Oxana; Sierkova, Valentyna; Storozhuk, Borys; Tseluyko, Vira; Vatutin, Mykola; Vayda, Myroslava; Vizir, Vadym; Volkov, Volodymyr; Voloshyna, Olena; Yagensky, Andriy; Zhurba, Svitlana; Zorin, Valeri